Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Tag

Non-regulated
alfapump® DSR study in Heart Failure patients with persistent congestion Ghent, BELGIUM – 1 June 2021 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that the first patient has been enrolled in the SAHARA DESERT study. Interim...
Read More
Ghent, BELGIUM – 10 March 2021 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, will announce its full year results ended 31 December 2020 on Wednesday, 17 March 2021. The management team will host a conference call with live...
Read More
Ghent, BELGIUM – 15 February 2021 – Sequana Medical NV (Euronext Brussels: SEQUA, the “Company”), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces that its management team will participate in the following upcoming virtual investor conferences. BTIG Virtual MedTech, Digital Health, Life Science &...
Read More
Ghent, BELGIUM – 4 February 2021 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, today announces the granting of key patents  for the alfapump DSR (Direct Sodium Removal) programme in the U.S. and European Union. U.S. patent number 10,898,631...
Read More
Ghent, BELGIUM – 17 December 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that its management team will participate in two upcoming virtual investor conferences, being held in parallel with the JP Morgan 39th Annual Healthcare Conference....
Read More
Live webcast with Dr. Jeffrey Testani on 11 December 2020 at 03:00 pm CET / 09:00 am EST Ghent, BELGIUM – 07 December 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that it will hold a key...
Read More
Ghent, BELGIUM – 12 November 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that Ian Crosbie, Chief Executive Officer, will present at the Jefferies 2020 Virtual London Healthcare Conference taking place from 17 to 19 November 2020....
Read More
Dr. Felker and Dr. Udelson join current advisors to support the development of alfapump® DSR for the management of fluid overload in patients with heart failure   Ghent, BELGIUM – 15 October 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart...
Read More
Ghent, BELGIUM – 09 September 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, today announces that it will participate in two virtual investor events in September 2020.   H.C. Wainwright & Co 22nd Annual Global Investment Conference, 14-16 September...
Read More
Ghent, BELGIUM – 27 August 2020 – Sequana Medical NV (Euronext Brussels: SEQUA), an innovator in the management of fluid overload in liver disease, malignant ascites and heart failure, will announce its results for the half year ended 30 June 2020 on Thursday, 3 September 2020. The management team will host a conference call with...
Read More
1 3 4 5 6 7 9

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES